Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca, China
AstraZeneca talks up US growth as China problems fester
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid a probe that has battered the drugmaker’s share price.
AstraZeneca chief says group takes China probe ‘very seriously’
AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of strong sales of cancer medicines.
AstraZeneca CEO says detained China chief has a lawyer but 'we have no information'
AstraZeneca's CEO said on Tuesday that the company's China president Leon Wang, who last month was detained by Chinese authorities, has a lawyer he is in touch with, but "we have no information as a company".
Pharma Giant AstraZeneca Takes China Probes 'Very Seriously'
British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that caused the detention of its China boss.
7h
on MSN
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
2d
on MSN
AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
Hosted on MSN
2d
AstraZeneca Expands U.S. Investment Plan
AstraZeneca
said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...
21h
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
2d
on MSN
AstraZeneca says detained China head has lawyer, but company still in dark
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...
Bisnow
1d
AstraZeneca To Invest $3.5B To Grow U.S. Footprint
Cambridge, England-based biopharmaceutical giant
AstraZeneca
is pouring billions of dollars into properties in the United ...
STAT
2d
Pharmalittle: We’re reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Reuters
2d
AstraZeneca: 450 million pound investment in UK under review amid talks with govt
LONDON, Nov 12 (Reuters) - London-listed drugmaker
AstraZeneca
(AZN.L), opens new tab said its plan to invest 450 million ...
MM&M
1d
AstraZeneca: New drug data, promising earnings and a $3.5B R&D investment
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
STAT
2d
AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
Business Insider
1d
AstraZeneca: Strong Q3 Growth and Strategic Moves Justify Buy Rating
Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on
AstraZeneca
(AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...
MarketWatch
2h
AstraZeneca rises Thursday, outperforms market
Shares of
AstraZeneca
PLC AZN advanced 1.46% to £102.92 Thursday, on what proved to be an all-around positive trading ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
China
Q3
United States
Pfizer
Tezspire
Feedback